ACCESSWIRE

Terry Lynch Joins BioNxt as Capital Markets Advisor

Share

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings decades of start-up and emerging growth capital markets experience in the resource and bioscience sectors, including finance and M&A, as well as an extensive and influential network of market professionals.

Mr. Lynch is currently the CEO of Power Nickel Inc., a publicly traded mining company with an advanced high grade polymetallic Nickel project based in Quebec, Canada, and is a cofounder of TSX and NASDAQ listed Cardiol Therapeutics, a market leader in pharmaceutical grade CBD production and the developer of groundbreaking therapies for the treatment of cardiovascular disease. He holds a joint honours degree in business administration and economics from St. Francis Xavier University.

Mr. Lynch is also the founder and managing director of Save Canadian Mining ("SCM"). Launched in November 2019, SCM is an industry lobby group created to support Canada's junior mining sector in requesting regulatory changes to Canada's capital markets. He was successful in unifying support from the TSX Venture Exchange, the Ontario Mining Association, the Ontario Prospectors Association, as well as mining industry leaders such as Eric Sprott (Sprott Mining), Sean Roosen (Osisko Mining), Keith Neumeyer (First Majestic Silver Corp), and Rod McEwan (McEwan Mining Inc.) and over 25 junior mining companies and over 5,000 individual members.

"It's quite an exciting time to be joining the BioNxt team," said Mr. Lynch. "Positive toxicology and PK results for their sublingual Cladribine product for MS give me confidence going into the upcoming human bioavailability study. And with the Company's recent patent news, I see a scalable opportunity for the accelerated development of multiple sublingual products for the treatment neurological disorders."

BioNxt's lead program is the development of a 100% owned and proprietary sublingual Cladribine dosage form, directed at the MS market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with 2023 annual sales in excess of one billion USD according to Merck KGaA. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is anticipated to top USD 41 billion by 2033 according to Market.us. BioNxt's sublingual Cladribine product is expected to yield a significant advantage over the tablet form for patients suffering from Dysphagia (difficulty swallowing), which is a common symptom among MS patients.

In the first half of 2024, the Company announced positive results for both its sublingual Cladribine animal toxicity study and animal pharmacokinetics ("PK") studies. The animal toxicity study results demonstrated zero adverse clinical abnormalities or indications of toxicity in any participants after consecutive days of dosing. The PK study results demonstrated highly comparable rapid absorption and bioequivalence between the Company's sublingual product and the name-brand reference drug for all administered samples. The next steps in the development and commercialization process include technology and process transfer, upscaling of manufacturing capability, analytical method development and validation, and clinical sample manufacturing preparation, manufacturing, and product release for use in the human comparative bioequivalence study planned for early Q1 2025. The bioequivalence study will be carried out with a European contract research organization in accordance with EU medical regulatory guidelines.

SOURCE: BioNxt Solutions Inc.

On September 9, 2024, BioNxt reported that the European Patent Office ("EPO") issued a positive international examination report for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, such as MS. The Company expects the EU patent to be granted within four weeks and to rapidly enter the national phase of the Patent Cooperation Treaty ("PCT") patent process with submissions planned for the US, Canada, China, Japan, Australia, and other jurisdictions.

BioNxt confirms that its second clinical indication using anticancer compounds in a sublingual drug delivery system will be Myasthenia Gravis ("MG"). MG is an autoimmune and neuromuscular disease characterised by muscle weakness and fatigue. MG patients also commonly experience Dysphagia whereby a sublingual product is expected to yield a significant advantage over conventional tablet forms. The global MG market is expected to reach USD 6.7 billion by 2032 according to Clinical Trials Arena.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

BioNxt Solutions Inc.

Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422

Cautionary Statement Regarding "Forward-Looking" Information

Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.

SOURCE: BioNxt Solutions Inc.



View the original press release on accesswire.com

BioNxt Solutions Inc.

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Loar Holdings Inc. Reports Q3 2024 Results, Upward Revision to 2024 and Initial 2025 Guidance13.11.2024 08:00:00 CET | Press release

WHITE PLAINS, NY / ACCESSWIRE / November 13, 2024 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the third quarter of 2024. Third Quarter 2024 Net sales of $103.5 million, up 25.0% compared to the prior year's quarter. Net income for Q3 2024 was $8.7 million, up $5.8 million compared to the prior year's quarter. Diluted earnings per share of $0.09. Adjusted EBITDA of $38.1 million, up 31.8% compared to the prior year's quarter. Net income margin for the quarter improved to 8.4% from the prior year's quarter of 3.4%. Adjusted EBITDA Margin for the quarter was 36.8% compared to 34.9% for the prior year's quarter. Adjusted Earnings Per Share of $0.15. "Our third quarter results showcased our continued execution across all four of our strategic value drivers," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "We again achieved record net sales and Adjusted EBITDA, driven by strong demand in bo

CallTower Expands Global In-Country Connectivity With Operator Connect for Microsoft Teams13.11.2024 03:00:00 CET | Press release

CallTower Expands High-Quality Operator Connect to 27 Countries, Enhancing Seamless Global Communication for Enterprises. SALT LAKE CITY, UT / ACCESSWIRE / November 13, 2024 / CallTower, a global leader in delivering cloud communication (unified communications, contact center, mobility, and collaboration) solutions, including Microsoft Teams, Webex by Cisco, and Zoom solutions, is excited to announce the significant expansion of its Operator Connect for Microsoft Teams service across the globe. CallTower has expanded its coverage to provide enterprise clients with high-quality, resilient voice solutions across 27 countries, further strengthening its ability to support seamless communication for global organizations. CallTower has expanded into LATAM and APAC building on their established presence in the US, Canada, and EMEA, further solidifying CallTower's commitment to enhancing global communications. As of today, CallTower Operator Connect is available in the following locations: Aus

Invest in Bogota Starts Working Agenda at the Web Summit in Portugal in Search of Investors12.11.2024 20:50:00 CET | Press release

LISBON, PORTUGAL / ACCESSWIRE / November 12, 2024 / The Web Summit, one of the most important technology congresses in the world, starts this Monday in Lisbon, Portugal. Invest in Bogota, an investment promotion agency, will be participating in the event to showcase the business opportunities the city has in the field of information technologies. During the event, more than 3,000 companies from 160 countries and more than 1,000 investors are expected to gather, with an attendance that could exceed 70,000 people, according to figures from the organizers. Invest in Bogota, through the entity's Investment Promotion Management, will seek to connect companies, startups and investors that are disruptive, innovative and outstanding in the industry, so that they can consider Bogota as an investment and business destination in Latin America. Panoramic view of Bogota, Colombia. It is worth noting that in recent years, Bogota has positioned itself as a nearshore platform to serve nearby markets,

New Podcast Examines Global Health Workforce Development and Health Worker Mobility12.11.2024 14:00:00 CET | Press release

"Care Anywhere" from CGFNS International now available on major podcast streaming sites PHILADELPHIA, PA / ACCESSWIRE / November 12, 2024 / CGFNS International, a worldwide leader in international credentials evaluation and certification to support health worker careers, has launched a podcast exploring health workforce challenges that are now at the very center of the global healthcare landscape. Care Anywhere - The Global Health Workforce Podcast Watch & Subscribe at cgfns.org/podcast Care Anywhere: The Global Health Workforce Podcast includes discussions with thought leaders and innovators who are tackling these issues, as well as the voices of health workers around the world who face these challenges every day of their lives. Topics revolve around practice evolution, workforce shortages, and the growing global demand for healthcare talent. Listeners and viewers can subscribe now through their favorite podcast streaming sites including Apple Podcast, Spotify, and YouTube, as well as

ToolsGroup Recognized as The Technology Leader in Retail and Supply Chain 2024 SPARK Matrix(TM) Categories by QKS Group12.11.2024 08:00:00 CET | Press release

Company earns top ratings for technology excellence and customer impact in the 2024 SPARK Matrix™ for Retail Forecasting and Replenishment and the 2024 SPARK Matrix™ for Global Supply Chain Inventory Optimization BOSTON, MA / ACCESSWIRE / November 12, 2024 / ToolsGroup, a leading provider of retail and supply chain planning solutions, has been named the technology leader in QKS Group's 2024 SPARK Matrix™ Retail Forecasting and Replenishment and their 2024 SPARK Matrix™ analysis of the Global Supply Chain Inventory Optimization market. QKS Group, a global advisory and research firm, evaluates vendors for its SPARK Matrix™ based on two key criteria: technology excellence and customer impact. ToolsGroup was named the leader in the 2024 SPARK Matrix™ for Retail Forecasting and Replenishment for its ability to optimize demand forecasting and deliver more strategic pre- and in-season replenishment and allocation strategies in complex retail environments. Leveraging AI and sophisticated deman

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye